Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 2/20 | 0.66 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.62 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.62 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.62 |
| ▸ | CALCR | P30988 | 4/20 | 0.61 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.58 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.58 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.58 |
| ▸ | NPY1R | P25929 | 1/20 | 0.56 |
| ▸ | NPY2R | P49146 | 1/20 | 0.56 |
| ▸ | NPY4R | P50391 | 1/20 | 0.56 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.56 |
| ▸ | F2 | P00734 | 1/20 | 0.56 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.56 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29416027 | 0.92 | MAPK8 (0.63) | APLNRMAPK8MAPK9MAPK10CALCR | |
| SCHEMBL29526390 | 0.90 | APLNR (0.64) | APLNRNPY1RNPY2RNPY4RNPY5R | |
| SCHEMBL30960478 | 0.90 | CALCR (0.66) | APLNRMAPK8MAPK9MAPK10CALCR | |
| SCHEMBL29525286 | 0.89 | NPY2R (0.68) | CALCRHCRTR1HCRTR2NPY1RNPY2R | |
| SCHEMBL31182848 | 0.89 | F2 (0.64) | CALCRHCRTR1HCRTR2NPY1RNPY2R | |
| SCHEMBL31296089 | 0.89 | APLNR (0.61) | APLNRMAPK8MAPK9MAPK10CALCR | |
| SCHEMBL29526046 | 0.89 | APLNR (0.64) | APLNRNPY1RNPY2RNPY4RNPY5R | |
| SCHEMBL29525577 | 0.89 | APLNR (0.64) | APLNRNPY1RNPY2RNPY4RNPY5R | |
| SCHEMBL29525147 | 0.88 | APLNR (0.63) | APLNRNPY1RNPY2RNPY4RNPY5R | |
| SCHEMBL29525492 | 0.88 | APLNR (0.64) | APLNROPRM1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12570729-B2 | Antibody fragment based antifungal conjugate selectively targeting candida | ABGENICS LIFESCIENCES PRIVATE LIMITED (IN) | 2026-03-10 | — | — | US | disclosed |
| US-20240092878-A1 | AN ANTIBODY FRAGMENT BASED ANTIFUNGAL CONJUGATE SELECTIVELY TARGETING CANDIDA | ABGENICS LIFESCIENCES PRIVATE LIMITED (IN) | 2024-03-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12570729-B2 | Antibody fragment based antifungal conjugate selectively targeting candida | SERPINH1, HM13, NGLY1 | APLNR 1340/4885MAPK8 3065/4885MAPK9 795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.